NOK 2.05
(0.0%)
Year | Revenue | Revenue Growth |
---|---|---|
2023 | - NOK | 0.0% |
2022 | - NOK | 0.0% |
2021 | - NOK | 0.0% |
2020 | - NOK | 0.0% |
2019 | - NOK | 0.0% |
2018 | - NOK | 0.0% |
2017 | - NOK | 0.0% |
2016 | - NOK | 0.0% |
Year | Revenue | Revenue Growth |
---|---|---|
2024 Q1 | - NOK | 0.0% |
2024 Q2 | - NOK | 0.0% |
2023 Q1 | - NOK | 0.0% |
2023 Q4 | - NOK | 0.0% |
2023 Q3 | - NOK | 0.0% |
2023 Q2 | - NOK | 0.0% |
2023 FY | - NOK | 0.0% |
2022 Q2 | - NOK | 0.0% |
2022 Q1 | - NOK | 0.0% |
2022 FY | - NOK | 0.0% |
2022 Q4 | - NOK | 0.0% |
2022 Q3 | - NOK | 0.0% |
2021 Q1 | - NOK | 0.0% |
2021 FY | - NOK | 0.0% |
2021 Q4 | - NOK | 0.0% |
2021 Q2 | - NOK | 0.0% |
2021 Q3 | - NOK | 0.0% |
2020 Q4 | - NOK | 0.0% |
2020 Q1 | - NOK | 0.0% |
2020 Q2 | - NOK | 0.0% |
2020 Q3 | - NOK | 0.0% |
2020 FY | - NOK | 0.0% |
2019 Q1 | - NOK | 0.0% |
2019 FY | - NOK | 0.0% |
2019 Q4 | - NOK | 0.0% |
2019 Q3 | - NOK | 0.0% |
2019 Q2 | - NOK | 0.0% |
2018 Q1 | - NOK | 0.0% |
2018 FY | - NOK | 0.0% |
2018 Q4 | - NOK | 0.0% |
2018 Q3 | - NOK | 0.0% |
2018 Q2 | - NOK | 0.0% |
2017 Q1 | - NOK | 0.0% |
2017 Q2 | - NOK | 0.0% |
2017 Q4 | - NOK | 0.0% |
2017 Q3 | - NOK | 0.0% |
2017 FY | - NOK | 0.0% |
2016 FY | - NOK | 0.0% |
Name | Revenue | Revenue Difference |
---|---|---|
Arctic Bioscience AS | 33.75 Million NOK | 100.0% |
Aqua Bio Technology ASA | 1.55 Million NOK | 100.0% |
ArcticZymes Technologies ASA | 118.93 Million NOK | 100.0% |
BerGenBio ASA | 354 Thousand NOK | 100.0% |
Hofseth BioCare ASA | 194.87 Million NOK | 100.0% |
PCI Biotech Holding ASA | 2.99 Million NOK | 100.0% |
Thor Medical ASA | - NOK | NaN% |